Erasca (ERAS) Other Non-Current Liabilities (2020 - 2026)
Erasca (ERAS) posted Other Non-Current Liabilities of $340000.0 for Q1 2026, down 14.79% on a QoQ basis from $399000.0 in Q4 2025, and up 35.46% year-over-year from $251000.0 in Q1 2025.
Erasca (ERAS) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Erasca's Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $340000.0 for Q1 2026.
- Quarterly Other Non-Current Liabilities rose 35.46% year-over-year to $340000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $340000.0 (up 35.46% YoY) and the FY2025 annual result came in at $399000.0, up 10.22% from the prior year.
- Other Non-Current Liabilities was $340000.0 for Q1 2026 at Erasca, down from $399000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $761000.0 in Q3 2023 and bottomed at $82000.0 in Q2 2024.
- A 5-year average of $444142.9 and a median of $397000.0 in 2025 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities jumped 262.66% — and 2024, when it slumped 88.24%.
- Erasca's Other Non-Current Liabilities stood at $573000.0 in 2022, then dropped by 1.22% to $566000.0 in 2023, then sank by 36.04% to $362000.0 in 2024, then climbed by 10.22% to $399000.0 in 2025, then fell by 14.79% to $340000.0 in 2026.
- Business Quant data shows ERAS's Other Non-Current Liabilities at $340000.0 in Q1 2026, $399000.0 in Q4 2025, and $395000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Erasca | 5.83 Bn | 5.58 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 340,000.00 |
| Dec 31, 2025 | 399,000.00 |
| Sep 30, 2025 | 395,000.00 |
| Jun 30, 2025 | 263,000.00 |
| Mar 31, 2025 | 251,000.00 |
| Dec 31, 2024 | 362,000.00 |
| Sep 30, 2024 | 340,000.00 |
| Jun 30, 2024 | 82,000.00 |
| Mar 31, 2024 | 559,000.00 |
| Dec 31, 2023 | 566,000.00 |
| Sep 30, 2023 | 761,000.00 |
| Jun 30, 2023 | 697,000.00 |
| Mar 31, 2023 | 630,000.00 |
| Dec 31, 2022 | 573,000.00 |
| Dec 31, 2021 | 158,000.00 |
| Dec 31, 2020 | 1.62 Mn |